Form 4: Senti Biosciences Director Brenda Cooperstone Acquires 43,900 Stock Options

Director Brenda Cooperstone reports acquisition of 43,900 Senti Biosciences stock options on March 7, 2025.

Summary

• On March 7, 2025, Brenda Cooperstone, a director of Senti Biosciences, Inc. (SNTI), acquired 43,900 stock options.
• The exercise price of these options is $3.52.
• The options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• The expiration date for these options is March 6, 2035.
• Following the transaction, Cooperstone directly owns 43,900 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which can be seen as a standard part of executive compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of stock options by a director may signal confidence in the company's future, potentially impacting shareholder sentiment positively.

Key Dates